A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms NABNEC
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 18 May 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
- 23 Mar 2015 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020 as reported by ClinicalTrials.gov record.